ADPT vs ILMN
ADPT: Adaptive Biotechnologies uses its proprietary immune medicine platform to decode the human immune system for cancer diagnostics and drug discovery. ILMN: Illumina provides the essential genetic sequencing and array platforms that power modern genomic research and clinical diagnostics.
Side-by-side fundamentals
| Metric | ADPT | ILMN | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $25.99 | $219.40 | |
| Market cap as of 2026-08-24 | $4.1B | $33.1B | |
| P/E as of 2026-08-24 | n/a | 34.73 | |
| PEG as of 2026-08-24 | n/a | 3.62 | |
| Net margin as of 2026-08-24 | -20.7% | +18.4% | ILMN higher |
| Gross margin as of 2026-08-24 | +75.6% | +66.4% | ADPT higher |
| Operating margin as of 2026-08-24 | -19.9% | +19.5% | ILMN higher |
| ROE as of 2026-08-24 | -32.6% | +31.1% | ILMN higher |
| ROA as of 2026-08-24 | -11.9% | +12.7% | ILMN higher |
| Debt / equity as of 2026-08-24 | 2.34 | 0.70 | ILMN lower |
| Revenue growth (YoY) as of 2026-08-24 | +50.1% | +4.9% | ADPT higher |
| Revenue CAGR (3y) SEC XBRL | +14.3% | -1.4% | ADPT higher |
| Beta as of 2026-08-24 | 2.14 | 1.46 | |
| 1-year return as of 2026-08-21 close | +105.8% | +121.0% | ILMN higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.